Apollomics Inc. (NASDAQ:APLM – Get Free Report) COO Yi-Kuei Chen bought 20,000 shares of Apollomics stock in a transaction dated Friday, August 14th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $300,000.00. Following the purchase, the chief operating officer owned 121,248 shares of the company’s stock, valued at approximately $1,818,720. This trade represents a 19.75% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Apollomics Price Performance
Shares of APLM stock traded down $0.04 during trading hours on Monday, reaching $23.36. 35,072 shares of the stock were exchanged, compared to its average volume of 30,338. Apollomics Inc. has a 12-month low of $3.66 and a 12-month high of $42.12. The company’s 50-day moving average price is $18.24 and its 200-day moving average price is $17.30.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings downgraded shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Apollomics presently has a consensus rating of “Sell”.
Institutional Trading of Apollomics
A hedge fund recently bought a new position in Apollomics stock. Kestra Advisory Services LLC purchased a new position in Apollomics Inc. (NASDAQ:APLM – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics at the end of the most recent quarter. 19.13% of the stock is currently owned by institutional investors.
Apollomics Company Profile
Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.
Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.
Read More
- Five stocks we like better than Apollomics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
